Fuxi Huang

机构：Panyu District Central Hospital

发表论文 21 篇 · 总被引 568 次 · h-index 9

代表论文

• Lenvatinib Combined With Transarterial Chemoembolization as First-Line Treatment for Advanced Hepatocellular Carcinoma: A Phase III, Randomized Clinical Trial (LAUNCH) (2022 · Journal of Clinical Oncology · 被引 452)
• Adjuvant Transarterial Chemoembolization With Sorafenib for Portal Vein Tumor Thrombus (2024 · JAMA Surgery · 被引 15)
• Anaplastic lymphoma kinase (ALK)-rearranged pulmonary pleomorphic carcinoma successfully treated with crizotinib (2018 · Journal of International Medical Research · 被引 14)
• Current Smoking has a Detrimental Effect on Survival for Epidermal Growth Factor Receptor (EGFR) and Anaplastic Lymphoma Kinase (ALK) negative Advanced non-squamous Non-small Cell Lung Cancer (NSCLC) Patients Treated with Pemetrexed Continuation Maintenance (2018 · Journal of Cancer · 被引 12)
• Impact of Weight Loss at Presentation on Survival in Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors (EGFR-TKI) Sensitive Mutant Advanced Non-small Cell Lung Cancer (NSCLC) Treated with First-line EGFR-TKI (2018 · Journal of Cancer · 被引 12)
• Meta-analysis of the incidence and risks of interstitial lung disease and QTc prolongation in non-small-cell lung cancer patients treated with ALK inhibitors (2017 · Oncotarget · 被引 11)